18% of post-Octane motions for fee awards granted

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

18% of post-Octane motions for fee awards granted

Six months on from the US Supreme Court’s Octane decision, about 18% of motions for fee awards have been granted according to an analysis by Glaser Weil

The analysis from Glaser Weil noted that as of October 28 approximately 75 district court decisions had involved motions for fee awards since the Octane decision. Of these, about 18% of the motions were granted during this post-Octane period – with 50 denying, 13 granting (six by defendants and eight by plaintiffs), 10 granting in part (four by defendants and six by plaintiffs) and two still pending additional briefing.

"Interestingly, where the motion was granted or granted in part, the patent plaintiffs were the slight majority of successful movants."

The law firm noted it did not analyse pre-Octane statistics. “But 18% does not seem to indicate an overwhelming trend to awarding fees,” it said. “Interestingly, where the motion was granted or granted in part, the patent plaintiffs were the slight majority of successful movants. So, these numbers also do not seem to indicate an overwhelming shift within the grant rate towards defendants.”

Of the 13 decisions awarding fees, only three came on a post-Octane remand or reconsideration. In Kilopass Tech v Sidense, the district court awarded fees to the defendant after having previously denied the parties’ cross motions for fees. In Integrated Technology v Rudolph Technologies, after its previous finding of wilfulness was vacated on appeal, the district court still found grounds to award fees on remand under Octane to the plaintiff. In Medtrica Solutions v Cygnus Medical, the district court awarded fees to the plaintiff upon reconsideration after previously denying the motion. Two cases are pending additional briefing.

Glaser Weil noted this means Octane did not “unleash a flood of motions for reconsideration” and the indication is that pending fee motions were not affected.

"As much as Octane would make it easier for successful defendants, it also lowered the standard for successful plaintiffs, including NPEs, to get their fees awarded."

Noting the effect on NPEs, Glaser Weil said it is possible that some NPEs may have shelved “dubious” cases that they might have filed otherwise, noting the recent drop in litigation. “But the numbers do not overtly indicate a particular statistical disadvantage to patent plaintiffs, such as NPEs,” it said. “In fact, not surprisingly, the superficial indications are that the lowered standard can affect both sides of litigation. As much as Octane would make it easier for successful defendants, it also lowered the standard for successful plaintiffs, including NPEs, to get their fees awarded.”

more from across site and SHARED ros bottom lb

More from across our site

Sunny Su explains how her team overcame challenges with orchard evidence collection to secure a favourable plant variety decision from China’s top court
Flexible working firm continues trajectory from 2025 with appointment of Matthew Grant and Letao Qin
Anousha Davies, associate and trademark attorney at Birketts, unpicks how the university’s reputation enabled it to see off a proposed trademark for ‘Cambridge Rowing’
IP lawyers, who say they are encouraging clients to build up ‘tariff resilience’, should treat the risks posed by recent orders as a core consideration in cross-border licensing
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
News of Via Licensing Alliance adding two new members and Nokia’s proposal to extend interim licences to Warner Bros Discovery and Paramount were also among the top talking points
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Cooley and Stikeman Elliott advised 35Pharma on the deal, which will allow GSK to get its hands on S235, an investigational medicine for pulmonary hypertension
Simon Wright explains why the UK should embrace the possibility of rejoining the UPC, and reveals how CIPA is reacting to this month’s historic Emotional Perception AI case at the UK Supreme Court
Matthew Grady of Wolf Greenfield says AI presents an opportunity in patent practice for stronger collaboration between in-house and outside counsel
Gift this article